What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Applied StemCell, Inc.

Home
United States
Milpitas, CA
Applied StemCell, Inc.

Applied StemCell provides industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) technology.

Headquartered in Milpitas, California. Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California.

10/09/2025

Join our Chief Scientific Officer, Ruby Tsai, Ph.D., and learn how we can Unlock Allogeneic Cell Therapy.

While autologous cell therapies have provided new options for cancer patients, the approach is logistically complex, expensive, and not scalable.

Hear what Ruby Tsai, Ph.D., has to say about how allogeneic cell therapy developers are addressing this durability roadblock, as well as how genome engineering and induced pluripotent stem cells (iPSCs) are making scalable allogeneic cell therapies possible.

The webinar “Unlocking Allogeneic Cell Therapy: Exploring Durable Approaches” will take place on Wednesday, October 22, at 8 am PT / 11 am ET.

📌Save your spot: https://bit.ly/4q3ekbk

10/03/2025

Cell and gene therapy developers have a gene knock-in problem.

Cell and gene therapies require the insertion of large, complex DNA constructs into patient cells, but current tools cannot reliably deliver these constructs in a way that is:
• Safe – precise, site-specific, with no harmful off-target events

• Efficient – high integration rates for scalable manufacturing

• Predictable – consistent and reliable gene expression

Without a better knock-in solution, the full potential of cell and gene therapies cannot be realized.

At Applied StemCell, our mission is to empower scientists in the cell and gene therapy space to bring more life-saving therapies to market—which is why we offer TARGATT™ and S-SELeCT™ large knock-in technologies.

Connect with Dolores Baksh, Ph.D., Ruby Tsai, Ph.D., or Heather Lundie on LinkedIn or through the partnering portal to learn more at Meeting on the Mesa.

09/26/2025

We’ll iPS-see you at the iPSC Drug Development Summit 👀

James Lulo, Ph.D., and Kaytrina Anchelia will be at the iPSC Drug Development Summit in Boston on October 1-2, 2025, to discuss how our TARGATT™ Hypo hiPSC Knock-in Kit accelerates your iPSC-based cell therapy development.

Our hypoimmunogenic iPSC platform comes pre-built with TARGATT™ large knock-in technology, allowing you to quickly insert additional immune evasion and disease modifying genes at the H11 safe harbor locus so you can move faster.

Reach out to James Lulo, Ph.D., and Kaytrina on LinkedIn to find a time to meet, and let’s unleash the full power of biology together.

09/22/2025

Let’s meet and eat at Ventura BioCenter!

Join our Business Development team in Thousand Oaks at Biotech Vendor Services, Inc.'s Community Life Science Event on September 25, to talk about how our genome engineering platforms help you move faster and learn more in mammalian cells.

Our TARGATT™ large knock-in technology enables cell line development for protein expression and library construction directly in mammalian cells, opening the door to more biologically relevant studies that other genome engineering methods such as CRISPR, lentivirus, and transposons can’t deliver.

Meet with Heather Lundie in Thousand Oaks to get the conversation started.

See you there 🤝

09/17/2025

We're thrilled to welcome Kaytrina Anchelia as a Director of Business Development. With nearly a decade of experience driving significant business growth at OmniaBio, iVexSol, and Akron Bio, she brings deep commercial expertise in the cell and gene therapy space.

Kaytrina will leverage her extensive experience to support developers in advancing their programs, forge strategic partnerships, and deliver exceptional value to our clients.

Her excitement and commitment to empowering our peers are exhilarating: “I believe the TARGATT™ genome engineering platform has the potential to solve some of the industry’s most pressing challenges, and I look forward to helping deliver that value to our partners.”

Please join us in welcoming Kaytrina in the comments below! 🎉 ⬇️

09/11/2025

Let’s partner at Meeting on the Mesa 2025

Our CEO Dolores Baksh, Ph.D., CSO Ruby Tsai, Ph.D., and VP of Sales and Marketing Michael Yurkovich, Ph.D. will be attending Meeting on the Mesa 2025.

We’d love to meet with you during the event to discuss how our TARGATT™ large knock-in technology accelerates and enables cell line development for therapeutic and screening applications.

We even offer kits with our hypoimmunogenic cell line that incorporates our pre-built TARGATT™ large knock-in technology, allowing you to move fast and insert additional immune evasion elements in a single reaction (up to 20kb, more with nested reactions).

We’re also looking for strategic collaborations in advancing in vivo therapies with S-SELeCT™—a genome engineering platform that ensures the safety of the next generation of cell and gene-based medicines and enables you to unleash the full power of biology.

There’s much to be discussed and limited slots to meet.

Schedule a time to meet now: https://bit.ly/461wH8D

08/22/2025

We have your DNA covered—and your appetite too.

Ask us about our kits at https://bit.ly/4lEOaYY's upcoming R&D Vendor Discovery Day in San Francisco on August 26 and learn about genome engineering without naked double-stranded breaks.

Enjoy complimentary food and drinks, and a raffle to win AirPods. See you there!

Register now for free: https://bit.ly/4fM7hio

08/21/2025

We’re excited to welcome Dolores Baksh, Ph.D., as our new CEO at Applied StemCell.

Dolores joins Applied StemCell with more than 20 years of leadership in the life sciences industry, including prior roles as founding CEO of Hyperius Biotech and CEO of TAAV Biomanufacturing Solutions.

Our company founder Ruby Tsai, Ph.D., will continue to guide scientific strategy, innovation, and strategic collaborations as President and Chief Scientific Officer (CSO).

The entire Applied StemCell team is energized for what’s ahead!

Read the full announcement here: https://bit.ly/45twTNx

07/30/2025

Grab a bite with our Business Development team in San Diego ☀️

Wesley and Heather will be at BVS’s Biotech Community Event at SOVA on August 5. Enjoy some tacos and beer while learning about how our TARGATT™ large knock-in platform can empower your mammalian genome engineering with minimal off-target effects.

See you there! 🌮🤝

07/03/2025

This Independence Day, we’re celebrating more than just our independence and freedom as a U.S.-based company—we're celebrating your ability to operate freely when we use MAD7 in your cell line engineering project.

Find out what it means to operate freely when choosing MAD7 vs. CRISPR/Cas9 for product development by clicking here: https://bit.ly/3TUwrkJ

At Applied StemCell, we’re here to support your cell line engineering projects. We've been empowering the scientific community for over 17 years, and routinely use MAD7 for gene editing in iPSCs, HEK293s, CHO cells, and other mammalian cell lines.

05/16/2025

WEBINAR: Getting cell therapies to IND faster: the advantages of off-the-shelf GMP iPSCs with a DMF

In the rapidly evolving cell therapy regulatory landscape, getting your cell therapy candidate to IND can be challenging. The process of procuring suitable donor material, reprogramming the cells under GMP requirements, and characterizing the iPSCs burns time and money.

Join our COO, Tim Largen, in our upcoming webinar as he discusses how off-the-shelf iPSC technology covered by a DMF benefits cell therapy development and overcomes the associated regulatory challenges.

Register now to secure your spot: https://bit.ly/43dJmm5

04/29/2025

Join us in New Orleans ✈️⚜️

Speak with Mike Yurkovich, Ph.D., and Heather Lundie at Booth 329 and learn how our TARGATT™ large knock-in technology can help you target your mammalian cell line engineering goals. Efficiently knock in genes at the transcriptionally active H11 locus and consistently express proteins—even hard-to-express proteins like membrane proteins—with TARGATT™.

We fuel your research and discovery in other ways, too. Our biologically relevant solutions in iPSC generation and differentiation, gene editing, and animal services are engineered to shorten timelines and ensure you can leave the lab confidently at the end of the day. Let’s work together to unleash the full power of biology and get more cell therapies to the market. Get started now with our business development experts at ISCT 2025 New Orleans. 🤝

Address

521 Cottonwood Drive Suite 111
Milpitas, CA
95035

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

http://appliedstemcell.com/

Alerts

Be the first to know and let us send you an email when Applied StemCell, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Applied StemCell, Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in Milpitas?

Our Story

Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovationfor biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.

We are currently focusing on three areas:

Cell line generation for bio-production and bioassays

Patient-relevant cell models for personalized medicine and

Physiologically predictive animal models of human diseases

We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.

Establishing disease-specific isogenic models

Developing master cell lines for antibody/protein production

Generating iPSCs from patients containing the corrected mutations or inserted genes for pre-clinical applications

Generating animal models (mouse/rat models)

Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression.

This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines.

We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.